ProposalWorkspaceFederal OpportunitiesDepartment of Defense

Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

Active HT9402-27-Q-9102 SolicitationDefense Health Agency (DHA)
The full text, documents and contacts of this bid come with a ProposalWorkspace plan.Get started

At a glance

Defense Health Agency of Defense Health Agency (DHA) posted this Solicitation on Nov 12, 2026. Responses are due Nov 30, 2026. NAICS 325412 (Pharmaceutical Preparation Manufacturing), product or service code 6505 (Drugs and Biologicals). Place of performance: Texas 78230. Solicitation number HT9402-27-Q-9102.

Solicitation details

General information

Solicitation number
HT9402-27-Q-9102
Notice type
Solicitation
Place of performance
Texas 78230

Classification

NAICS
325412Pharmaceutical Preparation Manufacturing
Product or service
6505Drugs and Biologicals

Agency

Department
Department of Defense
Sub-tier
Defense Health Agency (DHA)
Office
Defense Health Agency

Description

From SAM.gov

The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.

P&T COMMITTEE MEETING: The following February 2027 newly approved drugs will be reviewed:

    1. Atebrioz – Skeletal Muscle Relaxants and Combinations – Subclass: NA
    2. Emcitate – Thyroid and Antithyroid Agents – Subclass: NA
    3. Hibsago – Hepatitis B Agents – Subclass: NA
    4. Juvmo – Parkinsons Agents – Subclass: NA
    5. Zegfrovy – Lung Cancer – Subclass: EGFR+ NSCLC

The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-27-Q-9102.

Pre-quotation teleconference is on November 17, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.

Documents

9 files

Subscribe to download these 9 files.

  • DoD Formulary Placement of FDA Newly Approved Drugs.pdf
    83 KB · Nov 12, 2026
    Download
  • FAR 52-225-6-Certificate.pdf
    645 KB · Nov 12, 2026
    Download
  • Price Appendix FAQ NAD.pdf
    231 KB · Nov 12, 2026
    Download
  • Price List - Atebrioz - Skeletal Muscle Relaxants and Combinations - NA.xlsx
    45 KB · Nov 12, 2026
    Download
  • Price List - Emcitate - Thyroid and Antithyroid Agents - NA.xlsx
    45 KB · Nov 12, 2026
    Download
  • Price List - Hibsago - Hepatitis B Agents - NA.xlsx
    45 KB · Nov 12, 2026
    Download
  • Price List - Juvmo - Parkinsons Agents - NA.xlsx
    45 KB · Nov 12, 2026
    Download
  • Price List - Zegfrovy - Lung Cancer - EGFR NSCLC.xlsx
    45 KB · Nov 12, 2026
    Download
  • RFQ HT9402-27-Q-9102 NAD.pdf
    1.0 MB · Nov 12, 2026
    Download

Similar open bids

Same NAICS 325412

More from Defense Health Agency (DHA)

Open bids, other NAICS codes